Free Trial
→ Louis Navellier: “I'm dropping everything on May 13.” Here's why. (From Stansberry Research) (Ad)tc pixel
NASDAQ:PHIO

Phio Pharmaceuticals Q1 2026 Earnings Report

Phio Pharmaceuticals logo
$1.09 -0.05 (-4.04%)
As of 12:07 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Phio Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
-$0.24
Beat/Miss
N/A
One Year Ago EPS
N/A

Phio Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Phio Pharmaceuticals Announcement Details

Quarter
Q1 2026
Date
5/21/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

Phio Pharmaceuticals' Q1 2026 Press ReleasePress Release
(8-K)
Phio Pharmaceuticals' Q1 2026 Quarterly reportQuarterly report
(10-Q)

Phio Pharmaceuticals Earnings Headlines

Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15 ...
April 14, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-04/68180927-phio-pharmaceuticals-corp-phio-pharmaceuticals-announces-nobel-prize-winning-science-takes-on-skin-cancer-in-a-fireside-chat-with-force-family-off-296.htm
Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026
April 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/phio-pharmaceuticals-announces-presentation-centri-110000882.html
The AI stocks about to become worthless (and one that isn't)
Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being built at a classified government facility in Tennessee could make today's leading AI models obsolete overnight. He compares it to the iPhone moment that wiped out Nokia, BlackBerry, and Motorola. When this machine comes online, it will reportedly accelerate AI breakthroughs 360-fold - compressing five years of progress into five days. Navellier has identified specific stocks he'd sell before this hits, and one ticker he'd buy before May 5th.tc pixel
May 8 at 1:00 AM  |  InvestorPlace (Ad)
Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
March 31, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/68074142-phio-pharmaceuticals-corp-phio-pharmaceuticals-announces-agreement-with-u-s-cgmp-manufacturing-source-for-drug-product-ph-762-296.htm
Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring ...
March 23, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/phio-pharmaceuticals-announces-american-academy-110000744.html
Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office
March 16, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/67954313-phio-pharmaceuticals-corp-phio-pharmaceuticals-announces-a-groundbreaking-approach-to-treating-skin-cancer-in-a-fireside-chat-with-force-family-of-296.htm
See More Phio Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Phio Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Phio Pharmaceuticals and other key companies, straight to your email.

About Phio Pharmaceuticals

Phio Pharmaceuticals (NASDAQ:PHIO), Inc. (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.

Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion. The lead programs in its pipeline include PH‐762, being evaluated in collaboration with Janssen for solid tumor indications, and PH‐687, an internally developed candidate with potential in immuno‐oncology. Both candidates are currently in preclinical or early clinical testing, as the company seeks to validate safety, tolerability and proof-of‐mechanism in human studies.

In addition to its collaboration with Janssen, Phio has established partnerships with academic institutions and research organizations to explore the broader utility of TRiMTM in hard‐to‐treat cancers. The company’s R&D efforts are supported by preclinical data demonstrating potent gene knockdown and immune modulation, laying the groundwork for combination strategies with established immunotherapies.

Founded in 2014 and headquartered in Newtown, Pennsylvania, Phio Pharmaceuticals operates primarily in the United States while engaging with global research networks. The company is led by President and Chief Executive Officer Seth Hewitt, whose background in translational oncology and RNAi drug development guides Phio’s strategic direction and clinical advancement efforts.

View Phio Pharmaceuticals Profile
Earnings Tools